Basel Medical Group

Basel Medical Group EBITDA per Share

The EBITDA per Share of Basel Medical Group (BMGL) as of Nov 7, 2026 is 5.21 SGD. In the previous year, EBITDA per Share was -0.64 SGD — a change of -914.46% (higher).

EBITDA per Share

5.21SGD

YoY

-914.46%

Last updated:

EBITDA per Share of Basel Medical Group is 2026 5.21 SGD. EBITDA per Share of Basel Medical Group was 2025 -0.64 SGD. It decreases by -914.46% higher compared to the previous year.

The Basel Medical Group EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
1.91 SGD
Jan 1, 2023
0.14 SGD
Jan 1, 2024
0.15 SGD
Jan 1, 2025
-0.64 SGD
Jan 1, 2026
5.21 SGD
The Basel Medical Group EBITDA per Share history
YEAREBITDA per ShareYoY
5.21SGD-914.46%
-0.64SGD-533.63%
0.15SGD+8.10%
0.14SGD-92.84%
1.91SGD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Basel Medical Group Stock analysis

What does Basel Medical Group do? Basel Medical Group Ltd. generates revenue through orthopedic surgeries, medical care, and diagnosis services. The company offers a comprehensive range of orthopedic, trauma, and sports medicine services, including knee and hip replacements, spine surgery, foot and ankle procedures, and minimally invasive treatments. Its services encompass non-surgical options like medications, injections, splinting, and physiotherapy, alongside surgical procedures such as complex surgeries and minimally invasive techniques. The company also provides rehabilitative therapy, including in-house physiotherapy for post-surgery recovery and sports therapy, as well as neurosurgical care for spinal and brain conditions, covering treatments for headaches, brain tumors, spinal issues, aneurysms, and strokes. The primary customers for Basel Medical Group Ltd.'s services are patients requiring orthopedic, trauma, and sports medicine treatments, as well as those needing rehabilitative therapy or neurosurgical care. The company serves individuals seeking specialized medical care for conditions ranging from joint replacements to complex spinal and neurological disorders. Its offerings cater to a broad spectrum of medical needs, from routine orthopedic procedures to advanced neurosurgical interventions, ensuring comprehensive care for diverse patient segments. Basel Medical Group Ltd. operates as an investment holding company focused on healthcare services, with its revenue streams derived from delivering orthopedic surgeries, medical diagnostics, and therapeutic treatments. The company's service portfolio includes both non-surgical and surgical orthopedic care, rehabilitative therapy, and neurosurgical services, all aimed at addressing various medical conditions through specialized treatment options. Its business model relies on providing high-quality, specialized medical services to patients across multiple healthcare segments. Basel Medical Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Basel Medical Group stock

EBITDA per Share of Basel Medical Group is 5.21 SGD in 2026.

EBITDA per Share of Basel Medical Group changed from -0.64 SGD to 5.21 SGD, representing a -914.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Basel Medical Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Basel Medical Group

All Key Metrics — Basel Medical Group